Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 2757.82% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 1495.62% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 1495.62% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 3234.13% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 1495.62% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 3948.58% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 1495.62% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 1495.62% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 5139.34% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 376.3% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 376.3% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 495.38% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 376.3% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 1090.76% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 1805.22% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 1567.06% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/16/2023 | 2757.82% | 查丹资本 | 14 美元 → 12 美元 | 维护 | 购买 |
| 06/26/2023 | 1495.62% | EF Hutton | → 6.7 美元 | 重申 | 购买 → 购买 |
| 05/25/2023 | 1495.62% | EF Hutton | → 6.7 美元 | 假设 | → 购买 |
| 05/11/2023 | 3234.13% | 查丹资本 | 17 美元 → 14 美元 | 维护 | 购买 |
| 04/19/2023 | 1495.62% | EF Hutton | → 6.7 美元 | 重申 | → 购买 |
| 04/19/2023 | 3948.58% | 查丹资本 | 22 美元 → 17 美元 | 维护 | 购买 |
| 02/15/2023 | 1495.62% | EF Hutton | → 6.7 美元 | 重申 | → 购买 |
| 2022 年 12 月 19 日 | 1495.62% | EF Hutton | → 6.7 美元 | 启动覆盖开启 | → 购买 |
| 2022 年 9 月 22 日 | 5139.34% | 查丹资本 | $2 → 22 美元 | 维护 | 购买 |
| 08/16/2022 | 376.3% | 查丹资本 | 2.5 美元 → 2 美元 | 维护 | 购买 |
| 02/09/2022 | 376.3% | BTIG | 5 美元 → 2 美元 | 维护 | 购买 |
| 2021 年 12 月 20 日 | 495.38% | 查丹资本 | 8 美元 → 2.5 美元 | 维护 | 购买 |
| 2021 年 12 月 16 日 | 376.3% | HC Wainwright & Co. | → 2 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 9 月 15 日 | 1090.76% | BTIG | → 5 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 4 月 9 日 | 1805.22% | 查丹资本 | 7 美元 → 8 美元 | 维护 | 购买 |
| 2020 年 5 月 6 日 | 1567.06% | 查丹资本 | → 7 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet Biotherapeutics（SONN）的目标价格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on August 16, 2023. The analyst firm set a price target for $12.00 expecting SONN to rise to within 12 months (a possible 2757.82% upside). 9 analyst firms have reported ratings in the last year.
Chardan Capital于2023年8月16日公布了Sonnet Biotherapeutics（纳斯达克股票代码：SONN）的最新目标股价。这家分析公司将目标股价定为12.00美元，预计SONN将在12个月内升至12个月内（可能上涨2757.82％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
分析师对Sonnet Biotherapeutics（SONN）的最新评级是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.
Sonnet BioTherapeutics（纳斯达克股票代码：SONN）的最新分析师评级由Chardan Capital提供，Sonnet BioTherapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Sonnet BioTherapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Sonnet BioTherapeutics的最后一次评级是在2023年8月16日提交的，因此你应该预计下一个评级将在2024年8月16日左右公布。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析师对 Sonnet BioTherapeutics (SONN) 的评级正确吗？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $14.00 to $12.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.42, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Sonnet BioTherapeutics（SONN）评级维持不变，目标股价为14.00美元至12.00美元。Sonnet BioTherapeutics（SONN）目前的交易价格为0.42美元，超出了分析师的预测区间。